Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Biliary obstruction caused by the liver fluke, Fasciola hepatica

Takuya Ishikawa, Vanessa Meier-Stephenson and Steven J. Heitman
CMAJ April 19, 2016 188 (7) 524-526; DOI: https://doi.org/10.1503/cmaj.150696
Takuya Ishikawa
Division of Gastroenterology (Ishikawa, Heitman), Division of Infectious Disease (Meier-Stephenson), Department of Medicine, University of Calgary, Calgary, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vanessa Meier-Stephenson
Division of Gastroenterology (Ishikawa, Heitman), Division of Infectious Disease (Meier-Stephenson), Department of Medicine, University of Calgary, Calgary, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven J. Heitman
Division of Gastroenterology (Ishikawa, Heitman), Division of Infectious Disease (Meier-Stephenson), Department of Medicine, University of Calgary, Calgary, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: steven.heitman@ucalgary.ca
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

A 20-year-old previously healthy man presented to hospital with a two-day history of right upper quadrant pain and vomiting. Nine months earlier, he had immigrated to Canada from Sudan, but he had also lived in Djibouti and Ethiopia. Four months before he presented to hospital, he received a diagnosis of tuberculous lymphadenitis and a four-drug course of tuberculosis treatment was started. However, he was nonadherent after only two months of treatment. In addition, results from screening tests at that time showed evidence of schistosomiasis for which he was prescribed praziquantel.

On examination, he was alert and without jaundice or scleral icterus. He had right upper quadrant tenderness on abdominal examination, but there were no palpable masses. The remainder of his examination was unremarkable. Laboratory test results showed elevated liver enzymes (aspartate transaminase 133 [normal < 40] U/L, alanine transaminase 217 [normal < 41] U/L, alkaline phosphatase 166 [normal 38–126] U/L and γ-glutamyltransferase 459 [normal 8–61] U/L) and a normal total bilirubin. Transabdominal ultrasonography showed a distended gallbladder containing some debris (Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.150696/-/DC1) and a prominent common bile duct with a transverse diameter of 1.1 cm. A computed tomography scan of the abdomen also showed prominence of the common bile duct, but no calcified stone was identified (Appendix 1). A hepatobiliary iminodiacetic acid scan suggested distal obstruction in the common bile duct. Endoscopic retrograde cholangiopancreatography was performed and showed a normal major papilla without any trauma or inflammation. The cholangiogram showed an irregular defect in the common bile duct (Appendix 1). A sphincterotomy and sweep of the common bile duct with a balloon showed a living, brown, leaf-shaped flat worm (Figure 1; Appendix 2, video available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.150696/-/DC2). The organism was removed using a net basket, and the gross specimen was sent to pathology (Figure 2A). Praziquantel (25 mg/kg, three times daily for two days) was prescribed after the procedure at the recommendation of the infectious disease service. The patient was discharged without complications, and he had immediate symptomatic relief after endoscopic retrograde cholangiopancreatography. The specimen was subsequently identified as Fasciola hepatica (Figure 2) and treatment with triclabendazole was started. On follow-up examination three weeks later, he remained asymptomatic and test results showed that his liver enzyme levels were normal.

Figure 1:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1:

A flat, leaf-shaped, brown worm emerging from the common bile duct of a 20-year-old man with abdominal pain.

Figure 2:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2:

Photograph of the brown, leaf-shaped parasite (1.5 × 0.8 × 0.2 cm3 in size) extracted from the common bile duct of a 20-year-old man (A). Photomicrographs of the specimen showing the oral (black arrow) and ventral (black broken arrow) suckers (original magnification × 40) (B), branching intestines (original magnification × 100) (C) and spiked integument (original magnification × 200) (D). Using the patient’s immigration history from North Africa, the specimen was identified as the liver fluke, Fasciola hepatica. The size and lack of identifiable eggs indicate an immature adult form of the parasite.

Discussion

Helminthic infestation of the hepatobiliary system can result from roundworms, tapeworms and flat worms, such as flukes. These parasites differ in endemicity, clinical presentation and treatment; therefore, a thorough travel and exposure history is critical for establishing a diagnosis and management plan.1 Fasciola hepatica is endemic to South America, North Africa, Asia and Europe. The organism is typically found in areas where cattle or sheep are grazing within proximity to a water source, because both these larger mammals and a specific snail host are needed for the fluke to complete its life cycle.2,3 Although fascioliasis is far more common in developing countries, this case shows that parasitic infectious disease has become a global concern because of expanded world travel and immigration.

Different species of liver flukes have predilictions for either the intrahepatic or extrahepatic biliary tree. Clonorchis and Opisthorchis species prefer the intrahepatic biliary tree, whereas Fasciola hepatica and Fasciola gigantica prefer the extrahepatic bile ducts. In addition, the roundworm Ascaris also favours the extrahepatic biliary tree following its aberrant migration from the small intestine.1 The larvae of most flukes migrate retrograde up the biliary tree before settling; however, Fasciola species prefer to tunnel through the bowel wall and may spend up to 24 hours in the peritoneal cavity before locating the liver and penetrating the liver capsule into the parenchyma (hepatic stage).2 Once the Fasciola species is in the liver, it tunnels through the parenchyma to the biliary ducts and matures within the biliary system (biliary stage).4 While the fluke is tunneling, a peripheral blood smear often shows eosinophilia, which can be a clue to the presence of a parasitic infection.

Once the fluke is in the biliary system, test results will often show elevated cholestatic liver enzyme levels, and in endemic areas, this laboratory finding raises suspicion of the diagnosis.5 In nonendemic areas, elevated cholestatic liver enzyme levels associated with abdominal pain usually leads to workup for gallstone disease, which was our primary differential diagnosis (Box 1).6 Indeed, the patient presented with right upper pain, elevated liver enzyme levels and a dilated biliary tree, typical of a common bile duct stone.

Box 1:

Differential diagnosis of abdominal pain and raised hepatic enzymes1,5,6

View this table:
  • View inline
  • View popup
  • Download powerpoint

Infections caused by Fasciola species can be diagnosed by microscopic stool examination; however, immunologic techniques, such as enzyme-linked immunosorbent assay, play a more important role because they have 100% sensitivity and 97.8% specificity for fascioliasis.7 In this case, the stool analysis was negative for ova and parasites. Pathologically, liver flukes can be distinguished from one another based on their size, internal organ arrangement and integument features (Figure 2).8

Most liver fluke infections are treated with praziquantel.9 Praziquantel has a broad spectrum of activity and is the drug of choice for various trematodiasis, such as clonorchiasis, opisthorchiasis, paragonimiasis and intestinal fluke infections. However, fascioliasis responds poorly to praziquantel,10 and, thus, our initial choice of treatment was suboptimal. Triclabendazole is recommended for Fasciola infections.3 However, it is currently approved in only a few countries (e.g., Egypt and Peru)9 for use as a treatment for fascioliasis in humans. In Canada, it is necessary to make a request to Health Canada’s Special Access Programme for Drugs to obtain triclabendazole (www.hc-sc.gc.ca/dhp-mps/acces/drugs-drogues/index-eng.php).

Follow-up examination should ensure resolution of clinical symptoms, laboratory abnormalities (including eosinophilia, elevated liver enzyme levels and serologic titres) and radiologic findings (ultrasonographic biliary tract abnormalities).2 Endoscopic clearance of the biliary tree may also be necessary in some instances, because of the risk of biliary obstruction and its related complications, such as cholangitis and pancreatitis, that result from the presence of dead flukes after drug treatment.2

Key points
  • Fascioliasis is an uncommon cause of biliary obstruction in North America; however, expanded world travel and immigration make it a global concern.

  • Treatment should commence after the organism is identified; triclabendazole is first-line treatment for fascioliasis, but its availability is limited in Canada.

  • Endoscopic retrograde cholangiopancreatography is a useful tool for clearing the biliary tree of dead and living liver flukes.

Acknowledgements

The authors are grateful to Sydney Bass for supervising the procedure. The authors also thank Stephen Vaughan and Dan Gregson for their involvement in the diagnosis and input in the management of the case.

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

  • The authors have obtained patient consent.

  • A video showing a liver fluke (Hepatica fasciola) emerging from the patient’s common bile duct is available in Appendix 2, at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.150696/-/DC2.

  • Contributors: Takuya Ishikawa performed the procedure. Vanessa Meier-Stephenson led the discussion of the pathology and epidemiology. All of the authors drafted the article, reviewed it critically for intellectual content, approved the final version to be published and agreed to act as guarantors of the work.

References

  1. ↵
    1. Pockros PJ,
    2. Capozza TA
    . Helminthic infections of the liver. Curr Infect Dis Rep 2005;7:61–70.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Sezgin O,
    2. Altintas E,
    3. Disibeyaz S,
    4. et al
    . Hepatobiliary fascioliasis: clinical and radiologic features and endoscopic management. J Clin Gastroenterol 2004;38:285–91.
    OpenUrlCrossRefPubMed
  3. ↵
    Parasites — Fascioliasis (Fasciola Infection). Atlanta: Centers for Disease Control and Prevention; 2013. Available: www.cdc.gov/parasites/fasciola/biology.html (accessed 2015 Oct. 26).
  4. ↵
    1. Lim JH,
    2. Mairiang E,
    3. Ahn GH
    . Biliary parasitic diseases including clonorchiasis, opisthorchiasis and fascioliasis. Abdom Imaging 2008;33:157–65.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Marcos LA,
    2. Terashima A,
    3. Gotuzzo E
    . Update on hepatobiliary flukes: fascioliasis, opisthorchiasis and clonorchiasis. Curr Opin Infect Dis 2008;21:523–30.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Assy N,
    2. Jacob G,
    3. Spira G,
    4. et al
    . Diagnostic approach to patients with cholestatic jaundice. World J Gastroenterol 1999;5:252–62.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Al Qurashi H,
    2. Masoodi I,
    3. Al Sofiyani M,
    4. et al
    . Biliary fascioliasis — an uncommon cause of recurrent biliary colics: report of a case and brief review. Ger Med Sci 2012;10:Doc10.
  8. ↵
    1. Bennett CE
    . Scanning electron microscopy of Fasciola hepatica L. during growth and maturation in the mouse. J Parasitol 1975;61:892–8.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Keiser J,
    2. Utzinger J
    . Chemotherapy for major food-borne trematodes: a review. Expert Opin Pharmacother 2004;5:1711–26.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Patrick DM,
    2. Isaac-Renton J
    . Praziquantel failure in the treatment of Fasciola hepatica. Can J Infect Dis 1992;3:33–6.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 188 (7)
CMAJ
Vol. 188, Issue 7
19 Apr 2016
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Biliary obstruction caused by the liver fluke, Fasciola hepatica
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Biliary obstruction caused by the liver fluke, Fasciola hepatica
Takuya Ishikawa, Vanessa Meier-Stephenson, Steven J. Heitman
CMAJ Apr 2016, 188 (7) 524-526; DOI: 10.1503/cmaj.150696

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Biliary obstruction caused by the liver fluke, Fasciola hepatica
Takuya Ishikawa, Vanessa Meier-Stephenson, Steven J. Heitman
CMAJ Apr 2016, 188 (7) 524-526; DOI: 10.1503/cmaj.150696
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Azathioprine-induced severe anemia potentiated by the concurrent use of allopurinol
  • Schwannoma of the tongue
  • “Superscan” in diffusion-weighted imaging with background body suppression magnetic resonance imaging
Show more Practice

Similar Articles

Collections

  • Sections
    • Cases
  • Topics
    • Infectious diseases
    • Public health
    • Hepatology
    • General surgery

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire